BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Julian Harrison reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.
BTIG analyst Julian Harrison reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.